Clinical Trial Update: A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase II study investigating frontline pembrolizumab in Hodgkin lymphoma is in progress with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN